提供策略,结构修改和Honokiol的药理机制:全面的审查
Congying Pan1, Qing Li1, Shuxin Xiong1
1Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical Sciences, Chongqing University, No. 55 Daxuecheng South Road, Shapingba, Chongqing, 401331, P. R. China.
Chemistry & biodiversity
|February 3, 2024
概括
红 (HK) 是一种天然化合物,对各种疾病具有前景,但其生物可用性不佳. 纳米技术和化学修饰正在提高其在药物开发中的有效性.
科学领域:
- 药理学和自然产品化学化学
- 药物输送和纳米技术
- 药用化学 医学化学
背景情况:
- 红 (HK) 是一种生物活性化合物,来自马格诺利亚植物,具有多种治疗作用 (抗癌,抗炎,神经保护).
- 传统用途包括治疗焦虑,中风和流感症状.
- 低生物可用性和药理活性限制了HK的治疗潜力.
研究的目的:
- 审查诺基奥尔药理学活动的最新进展.
- 检查与药物相关的问题和改善HK特性 (溶解性,稳定性,生物可用性) 的策略.
- 要总结涉及HK的最近的专利和正在进行的临床试验.
主要方法:
- 评论关于Honokiol及其衍生物的最新科学文献.
- 分析使用基于纳米技术的配方的研究.
- 检查化学衍生和药物组合策略.
- 专利格局和临床试验数据的总结.
主要成果:
- 创新的HK配方 (纳米技术,化学衍生,药物组合) 显著提高了生物可用性和治疗疗效.
- HK衍生品和组合物在治疗癌症,炎症,感染和心血管/脑血管疾病方面表现出更好的活性.
- 最近的专利和临床试验表明,基于香港的药物开发取得了进展.
结论:
- 像纳米技术和化学修饰等策略有效地克服了霍诺基奥尔的局限性.
- 改进的HK配方对各种疾病具有显著的治疗潜力.
- 目前正在进行的研究和临床试验凸显了Honokiol在现代医学中日益重要的重要性.
相关概念视频
Drug Discovery: Overview
7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Drug Administration and Therapy Phases: Overview
468
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
468
Dose-Response Relationship: Overview
3.1K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.1K
Analgesia and Pain Management
623
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
623
Agonism and Antagonism: Quantification
376
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
376
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
515
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
515


